📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-17 18:02
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
8 announcements match the current filters (relevance ≥ 5).
Arvaya Healthcare to Consider Allotting 38.72 Lakh Shares for SIGPL Acquisition
Arvaya Healthcare Ltd has scheduled a Board meeting on October 24, 2026, to consider and approve the allotment of 38,71,854 equity shares on a preferential basis for consideration other than cash. The shares will be issued to the shareholders of Sushodha Institute of Gastroenterology Private Limited ('SIGPL'). At the current market price of Rs 116.0, this allotment translates to an implied transaction value of approximately Rs 44.9 crore, representing ~18% of the company's Rs 248 crore market cap. This signals an inorganic business addition for Arvaya Healthcare, which currently reports negligible TTM revenue.
Confidence: HIGH
What changedThe Board is convening to formally approve issuing 38.72 lakh equity shares to acquire or merge interests with SIGPL via a share swap.
Why it mattersArvaya Healthcare had zero TTM revenue and negative operating profits; acquiring SIGPL via equity swap represents a major strategic pivot and operational restructuring.
Shares to be allotted: 38,71,854Board meeting date: October 24, 2026Implied value of issue vs Market Cap: ~18.1%
📅 Short termMarket attention will focus on board approvals on October 24, 2026, and full disclosures regarding SIGPL's financials and shareholding dilution.
📈 Long termIf successfully executed, integrating SIGPL's healthcare assets could bring meaningful revenue and operational scale to a previously dormant entity.
⚠ Risk flags
- Equity dilution risk from issuing 38.72 lakh fresh shares
- Lack of detailed financial disclosures regarding SIGPL in the current intimation
- Execution and integration risks post-transaction
Key Highlights
Board meeting scheduled on October 24, 2026, to approve preferential share allotment
Allotment of 38,71,854 equity shares to shareholders of Sushodha Institute of Gastroenterology Private Limited (SIGPL)
Issue is on a preferential basis for consideration other than cash
Implied value of shares stands at ~Rs 44.9 crore based on the current market price of Rs 116.0
👀 What to Watch
Track the outcome of the October 24, 2026 board meeting for final approval, share issue pricing details, and the operational/financial profile of SIGPL.
Arvaya Healthcare Gets BSE In-Principle Nod for Rs 15.49 Cr Preferential Issue
Arvaya Healthcare has received in-principle approval from BSE dated October 12, 2026, for a preferential allotment of 38,71,854 equity shares. The shares carry a face value of Rs 10 each and are priced at an issue price of Rs 40 per share, implying a total fundraise of approximately Rs 15.49 crore. This proposed capital infusion equals about 6.2% of the company's current market capitalization of Rs 248 crore and represents about 26.7% of its existing net worth of Rs 58 crore. For a company with negligible TTM revenues (Rs 0 crore) and a TTM net loss of Rs -2 crore, the fresh capital provides liquidity but comes at a steep discount to the current market price of Rs 116.
Confidence: HIGH
What changedBSE granted in-principle approval to Arvaya Healthcare for issuing 38,71,854 equity shares at Rs 40 each on a preferential basis.
Why it mattersThe company secures clearance to raise Rs 15.49 crore to bolster liquidity, though the issue price of Rs 40 is at a sharp discount to the prevailing market price of Rs 116, leading to equity dilution.
Number of shares: 38,71,854Face value: Rs. 10/-Issue price: Rs. 40/-Estimated gross proceeds: Rs 15.49 CrFundraise vs Market Cap: ~6.2%Fundraise vs Net Worth: ~26.7%
📅 Short termApproval paves the way for board allotment; market may react to the pricing disparity between the Rs 40 issue price and the Rs 116 market price.
📈 Long termProvides balance sheet capital that could support business revival or new operations, given the company's near-zero operating revenue base.
⚠ Risk flags
- Equity dilution at Rs 40 per share, well below market price of Rs 116
- Company currently operates at near-zero revenue with ongoing net losses
Key Highlights
Received BSE in-principle approval on October 12, 2026
Approval granted for preferential issue of 38,71,854 equity shares
Face value fixed at Rs 10 per equity share
Issue price set at Rs 40 per share, totaling Rs 15.49 crore
👀 What to Watch
Track the formal allotment date, the lock-in conditions of the preferential shares, and detailed disclosure on end-use of proceeds to assess deployment.
Arvaya Healthcare Incorporates Insurance Broking Subsidiary with Rs 80 Lakh Initial Capital
Arvaya Healthcare has incorporated a wholly owned subsidiary, Arvaya Insurance Broking Private Limited, on September 17, 2026. The parent is investing Rs 80,00,000 in cash to subscribe to 8,00,000 equity shares of Rs 10 each (100% initial capital). The new entity has received an NOC from the Insurance Regulatory and Development Authority of India (IRDAI) to act as a Direct Insurance Broker in General and Life Insurance. This marks a diversification into financial services for the company, which reported near-zero revenue in FY26.
Confidence: HIGH
What changedArvaya Healthcare officially incorporated a 100% owned insurance broking subsidiary following receipt of an IRDAI NOC.
Why it mattersThe company has virtually zero operational revenue (Rs 0 Cr TTM); moving into insurance broking provides a new potential operating revenue stream.
Cost of subscription: Rs. 80,00,000/-Number of shares subscribed: 8,00,000 Equity SharesFace value per share: Rs. 10/- eachParent shareholding: 100%Investment vs Net Worth: ~1.38%
📅 Short termLow immediate operational impact as the subsidiary must complete remaining regulatory processes before generating revenue.
📈 Long termCould establish an active business line for a company currently lacking material core operating revenue, subject to final broking licenses and execution.
⚠ Risk flags
- Final operational broking license pending post-NOC
- Execution and monetization risk in a competitive broking market
- Disclosed filing delay under Regulation 30
Key Highlights
Incorporated wholly owned subsidiary 'Arvaya Insurance Broking Private Limited' on September 17, 2026
Cash subscription cost of Rs 80,00,000 for 8,00,000 equity shares of Rs 10 each
Received NOC from IRDAI to pursue Direct Insurance Broking in General and Life Insurance
Listed parent holds 100% initial paid-up share capital and control
👀 What to Watch
Track subsequent licensing milestones from IRDAI to commence commercial operations and monitor related capital expenditure or revenue contributions in upcoming quarterly reports.
Arvaya Healthcare approves up to ₹10 Cr IP acquisition in related-party transaction
Arvaya Healthcare's Board has approved the acquisition of the copyright and intellectual property portfolio of DEFIB INSTITUTE OF HEALTH SOLUTIONS LLP for a consideration not exceeding ₹10 crore. The transaction is structured strictly as an IP assignment and will be funded out of the proceeds of the company's Rights Issue. As a Material Related Party Transaction, it is subject to statutory compliance and shareholder approval under SEBI LODR regulations. The board revised the scope during the meeting from a previously planned slump-sale acquisition.
Confidence: HIGH
What changedThe Board revised its agenda and approved an IP portfolio acquisition from DEFIB INSTITUTE OF HEALTH SOLUTIONS LLP for up to ₹10 crore funded via Rights Issue proceeds.
Why it mattersRepresents a significant capital allocation (~17.2% of net worth of ₹58 crore) to related-party IP assets for a company with virtually zero operating revenue (TTM revenue near ₹0 Cr).
Max Acquisition Consideration: ₹10 CroresConsideration vs Net Worth (₹58 Cr): ~17.2%Consideration vs Market Cap (₹249 Cr): ~4.0%
📅 Short termMarket focus will center on shareholder approval dynamics and disclosures regarding the commercial relevance of the acquired IP.
📈 Long termThe company's turnaround hinges on whether the newly acquired IP can be successfully commercialized into sustainable operational revenue.
⚠ Risk flags
- Material related-party transaction governance and valuation risk
- Commercialization and monetization uncertainty of acquired IP
- Pending shareholder approval under SEBI LODR
Key Highlights
Acquisition consideration capped at not exceeding ₹10 Crores based on independent valuation
Funded out of proceeds from the company's Rights Issue
Structured strictly as an assignment of Copyright and IP portfolio, not a slump sale
Requires shareholder approval under SEBI LODR Regulation 23 for material related-party transactions
👀 What to Watch
Track the upcoming shareholder vote notice, independent valuation report details, and execution timeline for the definitive IP assignment agreement.
Arvaya Healthcare Board to Meet Aug 26 to Consider Slump Sale Acquisition of Navahmedi Solution
Arvaya Healthcare Ltd has scheduled a Board of Directors meeting on August 26, 2026, to consider and approve a related party transaction. The proposal involves acquiring the business undertaking of Navahmedi Solution Private Limited via a slump sale, encompassing intellectual property, assets, and liabilities. The acquisition is intended to be funded out of rights issue proceeds. Key financial details, including acquisition valuation and transaction consideration, will depend on the outcome of the board meeting.
Confidence: HIGH
What changedArvaya Healthcare has initiated formal board-level consideration for acquiring Navahmedi Solution Private Limited via slump sale.
Why it mattersWith the company reporting negligible TTM revenue and ongoing net losses, acquiring an operating business undertaking could alter its operational asset base, funded through rights issue capital.
Meeting Date: August 26, 2026Transaction Type: Slump sale (Related Party Transaction)Acquisition Consideration: not disclosedFunding Source: Rights issue proceeds
📅 Short termMarket attention will focus on the outcome of the board meeting on August 26, 2026, and subsequent disclosures regarding purchase price and asset quality.
📈 Long termIf approved and executed, the incoming assets and intellectual property could determine whether Arvaya Healthcare can establish sustainable commercial revenues.
⚠ Risk flags
- Related-party transaction risk regarding valuation and transfer terms.
- Lack of disclosed financial metrics regarding Navahmedi Solution Private Limited.
- Execution and integration risks following the slump sale.
Key Highlights
Board meeting scheduled for August 26, 2026 to evaluate the transaction.
Proposed acquisition of business undertaking from Navahmedi Solution Private Limited via slump sale.
Scope includes transfer of intellectual property, assets, and liabilities.
Acquisition to be funded utilizing proceeds from the company's rights issue.
👀 What to Watch
Track the outcome of the August 26, 2026 board meeting for disclosures on transaction valuation, valuation fairness reports, and shareholder approval requirements.
Arvaya Healthcare to enter Insurance Broking via new 100% Wholly Owned Subsidiary
Arvaya Healthcare has approved the incorporation of a wholly-owned subsidiary in India to enter the insurance broking service industry. This represents a significant strategic pivot for the company, which reported zero revenue throughout FY26 and the trailing twelve months. The commencement of operations is contingent upon obtaining regulatory approval from the Insurance Regulatory Development Authority of India (IRDA). With a current net worth of ‑‑58 Cr and a market cap of ‑‑143 Cr, the company is attempting to operationalize its business after a period of inactivity.
Confidence: HIGH
What changedThe company is transitioning from a non-operational entity into a regulated financial services provider by incorporating a new insurance broking subsidiary.
Why it mattersThis is a critical attempt to generate revenue for a company that currently has zero operational income; however, the insurance broking space is highly competitive and strictly regulated.
Proposed Ownership: 100%TTM Revenue: Rs 0 CrNet Worth: Rs 58 CrPromoter Holding: 30.62%Cost of Subscription: not disclosed
📅 Short termThe market may react to the intent of entering a new sector, but the impact will remain speculative until the subsidiary is incorporated and the IRDA license is applied for.
📈 Long termThe long-term viability depends entirely on the company's ability to secure a license and build a distribution network from scratch, given its lack of recent operational history.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Regulatory risk (IRDA approval is not guaranteed)
- Execution risk (no prior experience in insurance)
- Significant recent decline in promoter holding
- Zero current revenue base
Key Highlights
100% ownership of the proposed subsidiary to be held by Arvaya Healthcare Ltd
Entry into the Insurance Broking sector, moving away from its current dormant trading status
Mandatory regulatory approval required from IRDA before business commencement
Company reported Rs 0.0 Cr revenue in the most recent quarter ending March 2026
Promoter holding has significantly decreased from 62.73% in December 2025 to 30.62% in June 2026
👀 What to Watch
Investors should monitor the timeline for the IRDA license application and approval, as well as any disclosures regarding the capital infusion required for the new subsidiary.
Arvaya Healthcare Approves ₹370 Cr in Related Party Transactions and New Insurance Pivot
Arvaya Healthcare's board has approved material related party transactions (RPTs) totaling ₹370 crore for FY 2026-27 across nine entities, including promoters and subsidiaries. This is highly significant given the company reported zero revenue in FY26 and has a market capitalization of only ₹143 crore. The board also approved the incorporation of a new wholly-owned subsidiary to enter the General and Life Insurance broking business. Additionally, the company approved Q1 FY27 results and scheduled its 41st AGM for September 21, 2026.
Confidence: HIGH
What changedThe company is pivoting from a zero-revenue trading entity into insurance broking and has authorized transactions with related parties that are 2.5x its current market cap.
Why it mattersFor a micro-cap company with no current operational revenue, the scale of these RPTs and the entry into insurance represent a fundamental attempt to restart or transform the business model.
Total RPT Value: ₹370 croreRPT vs Market Cap: 258.7%Individual RPT Range: ₹40 - ₹50 croreAGM Date: September 21, 2026TTM Revenue: ₹0 crore
📅 Short termThe stock may see volatility as the market digests the scale of the proposed transactions and the new business direction.
📈 Long termThe long-term viability depends entirely on the execution of the insurance broking business and whether the related party transactions translate into actual consolidated revenue and profits.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Massive related-party transactions relative to company size
- Zero current operational revenue
- Significant business model pivot into a regulated sector (Insurance)
- High promoter holding volatility in the past year
Key Highlights
Approved ₹370 crore in total related party transactions for FY 2026-27 across 9 different entities
Individual RPTs with promoter-linked entities and subsidiaries range from ₹40 crore to ₹50 crore each
Proposed incorporation of a new Wholly Owned Subsidiary to act as a Direct Insurance Broker
41st Annual General Meeting (AGM) scheduled for September 21, 2026
Reconstituted the Nomination and Remuneration Committee to ensure regulatory compliance
👀 What to Watch
Investors should closely monitor the shareholder voting results for these massive related party transactions at the AGM on September 21, 2026, and look for the actual commencement of revenue in the new insurance subsidiary.
Arvaya Healthcare Approves ₹370 Cr Related Party Transactions and Insurance Broking Entry
Arvaya Healthcare has approved a massive ₹370 crore in material Related Party Transactions (RPTs) for FY 2026-27 across nine entities, including promoters and subsidiaries. This is highly significant given the company reported zero revenue in FY26 and has a market cap of only ₹143 crore. The board also approved a pivot into the insurance broking business through a new wholly-owned subsidiary. The 41st Annual General Meeting (AGM) is scheduled for September 21, 2026, where shareholders will vote on these RPTs.
Confidence: HIGH
What changedThe company is transitioning from a period of zero revenue into an active business phase involving massive related-party dealings and a new entry into the insurance broking sector.
Why it mattersThe proposed RPTs (₹370 Cr) are approximately 2.6 times the company's total market capitalization, representing a major shift in operations for a firm that has been financially inactive.
Total Approved RPT Value: ₹370 croreRPT Value vs Market Cap: 258.7%TTM Revenue: ₹0 croreAGM Date: September 21, 2026Promoter Holding (Jun 2026): 30.62%
📅 Short termThe stock may experience volatility as the market digests the scale of the RPTs and the pivot into insurance broking ahead of the AGM.
📈 Long termThe long-term viability depends on the successful execution of the insurance broking business and whether the large RPTs translate into actual revenue and profit for the listed entity.
⚠ Risk flags
- Massive Related Party Transactions (₹370 Cr) relative to company size
- Zero revenue in the trailing twelve months
- Significant reduction in promoter holding from 62.7% to 30.6% within a year
- Entry into a highly regulated insurance sector with no prior track record
Key Highlights
Approved ₹370 crore in Related Party Transactions for FY 2026-27 across 9 different entities
Proposed incorporation of a new Wholly Owned Subsidiary to act as a Direct Insurance Broker
Scheduled the 41st Annual General Meeting for September 21, 2026
Reconstituted the Nomination and Remuneration Committee to fix a compliance gap by replacing an Executive Director with an Independent Director
Approved the appointment of Mr. Kaushal Shah as Managing Director, liable to retire by rotation
👀 What to Watch
Investors should closely monitor the AGM on September 21, 2026, specifically the shareholder approval for the ₹370 crore RPTs. Given the company's zero revenue status, the nature and execution of these large-scale transactions are critical to understand.
